Study reveals how cancer cells thrive in oxygen-starved tumors

February 4, 2014

A new study identifies the molecular pathway that enables cancer cells to grow in areas of a tumor where oxygen levels are low, a condition called hypoxia.

The findings by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), might offer a new strategy for inhibiting by developing agents that reverse this hypoxia-related pathway.

The study focuses on how cancer cells use the amino acid glutamine, the most common amino acid found free in the bloodstream. Under normal , healthy cells use glutamine largely to produce energy, with a small amount diverted to make fatty acids and lipids.

But when oxygen levels drop in areas of a growing tumor, the hypoxic conditions activate a gene called HIF1, initiating a pathway that shifts the use of glutamine away from energy production and to the synthesis of lipids needed for cell proliferation.

The findings were published in the journal Cell Metabolism.

"These results are particularly exciting because glutamine metabolism is a potential target for anticancer therapy," says principal investigator Nicholas Denko, PhD, MD, associate professor of radiation oncology at the OSUCCC – James.

"Tumor cells require glutamine to grow, so groups have been trying to identify drugs that block glutamine metabolism and inhibit tumor growth. However, drugs that completely block glutamine metabolism will have unwanted side effects because glutamine is also an important neurotransmitter," he says.

"We show that we can block the growth of model tumors by redirecting hypoxic glutamine metabolism to make it follow the normal-oxygen pathway. Such a therapeutic strategy should have few-if-any unwanted side effects, because normal tissue is oxygenated and already using glutamine in the normal manner," says Denko, who is a member of the OSUCCC – James Molecular Biology and Cancer Genetics Program.

Denko and first author Ramon C. Sun, a postdoctoral researcher in radiation oncology, used several tumor-cell lines and an animal model for this study. Their key findings include:

  • Hypoxia activates HIF1, leading to the breakdown of the enzyme called OGDH2, which is necessary for the typical use of glutamine to produce energy via the tricarboxylic acid, or Krebs cycle.
  • When OGDH2 is lost, hypoxic divert glutamine away from energy production and use it to generate citrate that is then used to produce the lipids needed for cell proliferation.
  • Tumors with malignant cells that are forced to express a hypoxia-resistant form of OGDH2 grew significantly slower in an animal model than tumors with normal OGDH2, suggesting that reversing this hypoxic pathway might be an effective strategy for inhibiting tumor growth.

Explore further: Scientists find potential loophole in pancreatic cancer defenses

Related Stories

Scientists find potential loophole in pancreatic cancer defenses

March 27, 2013
Dana-Farber Cancer Institute scientists and colleagues have discovered that pancreatic cancer cells' growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted drugs to control ...

Cancer cells feed on sugar-free diet

January 10, 2012
(Medical Xpress) -- Cancer cells have been long known to have a “sweet tooth,” using vast amounts of glucose for energy and for building blocks for cell replication.  

How cancer cells get by on a starvation diet

November 21, 2011
Cancer cells usually live in an environment with limited supplies of the nutrients they need to proliferate — most notably, oxygen and glucose. However, they are still able to divide uncontrollably, producing new cancer ...

Targeting downstream proteins in cancer-causing pathway shows promise in cell, animal model

November 13, 2012
The cancer-causing form of the gene Myc alters the metabolism of mitochondria, the cell's powerhouse, making it dependent on the amino acid glutamine for survival. In fact, 40 percent of all "hard-to-treat" cancers have a ...

Triple-negative breast cancer target for drug development identified

October 3, 2013
Often deadly "triple-negative" breast cancers might be effectively treated in many cases with a drug that targets a previously unknown vulnerability in the tumors, according to a UC San Francisco researcher who described ...

Number of cancer stem cells might not predict outcome in HPV-related oral cancers

January 22, 2014
(Medical Xpress)—New research from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) suggests that it may be the quality ...

Recommended for you

Clinical trial suggests new cell therapy for relapsed leukemia patients

November 20, 2017
A significant proportion of children and young adults with treatment-resistant B-cell leukemia who participated in a small study achieved remission with the help of a new form of gene therapy, according to researchers at ...

Researchers discover a new target for 'triple-negative' breast cancer

November 20, 2017
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.

Study reveals new mechanism used by cancer cells to disarm attacking immune cells

November 20, 2017
A new study by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James) identifies a substance released by pancreatic cancer cells that protects ...

Cell-weighing method could help doctors choose cancer drugs

November 20, 2017
Doctors have many drugs available to treat multiple myeloma, a type of blood cancer. However, there is no way to predict, by genetic markers or other means, how a patient will respond to a particular drug. This can lead to ...

Lung cancer triggers pulmonary hypertension

November 17, 2017
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart ...

Researchers discover an Achilles heel in a lethal leukemia

November 16, 2017
Researchers have discovered how a linkage between two proteins in acute myeloid leukemia enables cancer cells to resist chemotherapy and showed that disrupting the linkage could render the cells vulnerable to treatment. St. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.